恩格列净治疗2型糖尿病肾病的临床观察

Abstract
Figure/Table
References (20)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical efficacy of Empagliflozin in the treatment of early type 2 diabetic nephropathy.Methods A total of 40 patients with type 2 diabetic nephropathy admitted to Fangshan District First Hospital of Beijing from December 2018 to February 2020 were selected as the research objects,and divided into the control group(20 cases)and the study group(20 cases)according to the random number table method.On the basis of the original hypoglycemic agents,renin angiotensin system blockers and the statins,the control group was treated with Siglitazine,and the study group was treated with Empagliflozin,both groups were treated for 24 weeks.Fasting plasma glucose(FPG),2 hours postprandial blood glucose(2 h PBG),glycosylated hemoglobin(HbA1c),blood lipid(including triacylglycerol[TG],total cholesterol[TC],high density lipoprotein cholesterol[HDL-C],low density lipoprotein cholesterol[LDL-C]),uric acid(UA),body mass index(BMI),blood pressure(including systolic pressure[SBP]and diastolic pressure[DBP]),albumin-to-creatinine ratio(ACR)and estimated glomerular filtration rate(eGFR)were compared between the two groups,and adverse reactions were recorded.Results After treatment,the levels of FPG,2 h PG and HbA1c in the two groups were lower than those before treatment,and the differences were statistically significant(P＜0.01).After treatment,there was no significant difference in the levels of FPG,2 h PG,HbA1c between the study group and the control group(P＞0.05).After treatment,the TG levels of the two groups were lower than those before treatment,and the TG level of the study group was lower than that of the control group,the differences were statistically significant(P＜0.05).The HDL-C levels of the two groups were higher than those before treatment,and the HDL-C level of the study group was higher than that of the control group,the differences were statistically significant(P＜0.05).Before and after treatment,there were no significant difference of the TC and LDL-C levels between the two groups(P＞0.05).After treatment,the levels of UA,BMI,SBP,DBP,ACR in the two groups were lower than those before treatment,and the levels of UA,BMI,SBP,DBP,ACR in the study group was lower than that in the control group,the differences were statistically significant(P＜0.05).Before and after treatment,there was no significant difference of the eGFR level between the two groups(P＞0.05).There was no obvious adverse reaction in both groups.Conclusion Empagliflozin treatment of early type 2 diabetic nephropathy can effectively reduce urinary protein excretion,delay the progression of diabetic nephropathy,and good safety,which is worthy of clinical application.

Key words： Empagliflozin Type 2 diabetes mellitus Diabetic nephropathy Efficacy

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Hong-dan
	FAN Jing

Cite this article:

LIU Hong-dan,FAN Jing. Clinical observation of Empagliflozin in the treatment of type 2 diabetic nephropathy[J]. 中国当代医药, 2021, 28(14): 84-88.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I14/84

[1]	王薇，张婷婷，贾冰，等.达格列净片对糖尿病肾病患者尿蛋白的影响[J].中国临床药理学杂志，2019，35（10）：947-949.
[2]	林善锬.肾素血管紧张素系统阻断与临床：概述与新手段[J].中华高血压杂志，2017，25（9）：823-825.
[3]	邓蕾蕾.羟苯磺酸钙治疗糖尿病肾病的安全性及效果分析[J].现代诊断与治疗，2018，29（12）：1926-1927.
[4]	Cherney DZ，Cooper ME，Tik kanen I，et al.Pooled analysis of Phase 3 trials indicate contrasting in fluences of renal function on blood pressure，body weight，and HbA1c reductions with empagliflozin[J].Kidney Int，2018，93（1）：231-244.
[5]	中华医学会内分泌学分会.中国成人糖尿病肾脏病临床诊断的专家共识[J].中华内分泌代谢杂志，2015，31（5）：379-385.
[6]	Cohen DL，Townsend RR.Blood pressure goals，variability and SGLT2 blockade in CKD[J].Nat Rev Nephrol，2017，13（2）：75-76.
[7]	Look AHEAD Research Group.Effect of a long-behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes：a secondary analysis of the Look AHEAD randomised clinical trial[J].Lancet Diabetes Endocrinol，2014，2（1）：801-809.
[8]	Tsimihodimos V，Filippatos TD，Elisaf MS.SGLT2 inhibitors and the kidney：Effects and mechanisms[J].Diabetes Metab Syndr，2018，12（6）：1117-1123.
[9]	Zhao Y，Xu L，Tian D，et al.Effects of sodium-glucose cotranspor（SGLT2）inhibitors on serum uric acid level：a metaanalysis of randomized controlled trails[J].Diabetes Obes Metab，2017，17（5）：1-5.
[10]	刘圆，孟浩宇，杨志健.钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭治疗中的研究进展[J].中国心血管杂志，2019，24（1）：86-88.
[11]	谷庆炜，李倩.钠－葡萄糖协同转运蛋白2抑制剂治疗糖尿病肾病的研究进展[J].医学综述，2018，24（17）：3447-3451.
[12]	Pradeepa R，Mohan V.Prevalence of type 2 diabetes and its complications in India and economic costs to the nation[J].Eur J Clin Nutr，2017，71（7）：816-824.
[13]	刘顺瑶，李佳，刘菊红，等.新型降糖药物治疗糖尿病肾脏疾病作用的研究进展[J].中国糖尿病杂志，2019，27（11），870-871.
[14]	MacIsaac RJ，Jerums G，Ekinci EI.Cardio-renal protection with empagliflozin[J].Ann Transl Med，2016，4（2）：409.
[15]	Cherney D，Lund SS，Perkins BA，et al.The effect of sodium-glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes[J].Diabetologia，2016，59（9）：1860-1870.
[16]	Vallon V，Thomson SC.Targeting renal glucose reabsorption to treat hyperglycaemia：the pleiotropic effects of SGLT2 inhibition[J].Diabetologia，2017，60（2）：215-225.
[17]	Li CG，Zhang J，Xue M，et al.SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart[J].Cardiovasc Diabetol，2019，18（1）：15.
[20]	卢志伟，赵振宇.SGLT-2抑制剂类药物临床作用特点及不良反应概述[J].国际医药卫生导报，2019，25（2）：331-333.
[18]	Lei Y，Devarapu SK，Motrapu M，et al.Interleukin-1β inhibition for chronic kidney disease in obese mice with type 2 diabetics[J].Front Immunol，2019，29（10）：1223-1233.
[19]	Delanaye P，Scheen AJ.Preventing and treating kidney disease in patients with type 2 diabetes[J].Expert Opin Pharmacother，2019，20（3）：277-294.